Metavia INC 8-K filings

MetaVia Inc. reports positive top-line results from its Phase 1 clinical trial of DA-1726, a novel dual agonist for obesity, showcasing dose-dependent weight loss and a favorable safety profile.

MetaVia Inc. reports the exercise of pre-funded warrants and provides an update on its corporate presentation and clinical programs targeting obesity and MASH.

MetaVia Inc. reports positive top-line data from its Phase 1 clinical trial of DA-1726, showing compelling weight loss and safety effects for obesity treatment.

MetaVia Inc. reports its year-end 2024 financial results, highlighting progress in clinical development of its cardiometabolic assets, DA-1726 and DA-1241, and anticipates key data readouts and regulatory meetings in 2025.

MetaVia Inc. released positive topline results from its Phase 2a trial of DA-1241 for MASH, showing significant improvements in liver health markers and plans to meet with the FDA in the first half of 2025.

MetaVia's DA-1241 shows positive top-line results in a Phase 2a clinical trial for MASH, demonstrating significant reductions in key liver and metabolic markers.

MetaVia Inc. released an updated corporate presentation highlighting the progress of its clinical programs for obesity and MASH, along with financial and strategic details.

NeuroBo Pharmaceuticals has changed its name to MetaVia Inc. and will trade under the ticker symbol MTVA, reflecting a strategic shift towards cardiometabolic disease treatments.

NeuroBo Pharmaceuticals reported positive top-line data from a Phase 1 trial for its obesity treatment, DA-1726, and anticipates key data readouts for both DA-1726 and DA-1241 in the coming months.

NeuroBo Pharmaceuticals has completed the last patient visit in its Phase 2a clinical trial for DA-1241, a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), with topline data expected in December 2024.

NeuroBo Pharmaceuticals has released an updated corporate presentation highlighting the progress of its obesity and MASH drug candidates, DA-1726 and DA-1241, respectively.

NeuroBo Pharmaceuticals reports positive top-line safety, tolerability, and pharmacokinetics data from the single ascending dose part of its Phase 1 trial for obesity treatment DA-1726.

NeuroBo Pharmaceuticals' stockholders approved proposals for a share issuance related to warrant exercises and the potential adjournment of a special meeting to solicit additional proxies.

NeuroBo Pharmaceuticals reported its second quarter 2024 financial results, highlighted by a successful $70 million financing and advancements in clinical trials for its cardiometabolic drug candidates.

NeuroBo Pharmaceuticals has completed enrollment for the single ascending dose (SAD) portion of its Phase 1 clinical trial of DA-1726 for obesity treatment, with top-line data expected in the third quarter of 2024.

NeuroBo Pharmaceuticals has partnered with Dong-A ST and ImmunoForge to develop a once-monthly formulation of DA-1726 for obesity treatment, leveraging ImmunoForge's ELP technology.

NeuroBo Pharmaceuticals has granted MThera Pharma exclusive rights to develop and commercialize NB-01 for painful diabetic neuropathy, including potential Phase 3 trials in the US and South Korea.

NeuroBo Pharmaceuticals has released an updated corporate presentation highlighting the progress of its clinical programs for obesity and MASH, along with recent financial updates.

NeuroBo Pharmaceuticals has closed a $70 million financing round and dosed the first patient in the Phase 1 multiple ascending dose trial for its obesity drug candidate, DA-1726.

NeuroBo Pharmaceuticals has secured $20 million through a concurrent private placement and registered direct offering, with the potential for an additional $50 million upon the exercise of clinical milestone-linked warrants.

NeuroBo Pharmaceuticals' DA-1726 demonstrated superior weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide in pre-clinical models, with additional data showing superior cholesterol suppression compared to tirzepatide.

NeuroBo Pharmaceuticals' stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the potential share issuance, and elected three Class II directors at their annual meeting on June 7, 2024.

Pre-clinical data suggests that NeuroBo's DA-1241, when combined with semaglutide, demonstrates improved liver fibrosis and hepatoprotective effects in MASH models compared to either treatment alone.

NeuroBo Pharmaceuticals announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in clinical trials for its obesity and MASH treatments.

NeuroBo Pharmaceuticals will present pre-clinical data on its drug candidates DA-1241 and DA-1726 at the EASL Congress 2024 and the American Diabetes Association 84th Scientific Sessions in June.

NeuroBo Pharmaceuticals has dosed the first patient in its Phase 1 clinical trial for DA-1726, a novel dual agonist for obesity treatment, and has accelerated trial timelines.

NeuroBo Pharmaceuticals has released an updated corporate presentation detailing the progress of its clinical programs for obesity and MASH, along with financial and strategic updates.

NeuroBo Pharmaceuticals has completed enrollment for the first part of its Phase 2a clinical trial evaluating DA-1241 for the treatment of MASH.

NeuroBo Pharmaceuticals reported its 2023 financial results and provided updates on its clinical programs for MASH and obesity, including the advancement of DA-1241 and DA-1726.

NeuroBo Pharmaceuticals announced that its Phase 2a trial for DA-1241, a potential treatment for MASH, has been recommended to continue without modification after a positive safety review.